Logo

CV Philippe Menasché

Philippe Menasché

Profesor (PU-PH)
TEAM LEADER – REGENERATIVE THERAPIES FOR CARDIAC AND VASCULAR DISEASE
Mail : philippe.menasche@aphp.fr
PHONE :+33 1 56 09 36 21

 

PubMed Publication

SCIENTIFIC TOPICS

  • Stem cells

  • Cardiac cell therapy

  • Extracellular vesicles

  • Heart failure

AVIESAN Resume

ITMO

  • Physiopathology

  • Metabolism

  • Nutrition

ORCID Resume

Biosketch

  • Medical Doctor at the Faculté de Médecine de Paris (MD degree, 1979)

  • Sciences Doctor at the Faculté des Sciences de Paris-Orsay (PhD degree, 1987)

  • Senior staff surgeon, Department of Cardiovascular Surgery, Hôpital Européen Georges Pompidou (1988-present)

Academic position

  • Professor of Thoracic and Cardiovascular Surgery (1988)

  • Visiting Professor, Department of Biomedical Engineering, University of Alabama in Birmingham, Birmingham (USA; 2018-present)

Participation to scientific committees

  • Director, Laboratory of Biosurgical Research of the Carpentier Foundation (2002-2018)

  • Core Member of the European Society of Cardiology Working Group “Cardiovascular Regenerative & Reparative Medicine” (2017-present)

  • Member of the National Council of Universities (nominated, then elected; 2010-2019)

  • Member (currently, President) of the Medical and Scientific Council of the Agency of Biomedicine (2012-present)

Awards

  • Prix Lamonica de cardiologie de l’Académie des Sciences (2010)

  • Earl Bakken Scientific Achievement Award (2011)

  • Grand Prix de la Fondation de France (2013)

  • Prix Yvette Rouannet de la Fondation pour la Recherche Médicale (2014)

  • Prix Matmut de l’Innovation Médicale (2014)

  • Prix Galien, volet “Travaux de recherche” (2016)

Scientific summary

While the initial research has focused on the transplantation of skeletal myoblasts (first-in-man implantation in 2000), it then moved towards the combination of cardiac progenitors derived from human embryonic stem cells (ESC) with a tissue engineering-based construct. The first-in-man trial testing this cell-loaded patch has now been successfully completed. In parallel, mechanistic studies have unraveled the predominant role of paracrine signaling and, consequently, the group has shifted its research towards a-cellular cell therapy based on the exclusive use of the secretome with the objective of further streamlining the clinical translatability of this myocardial repair strategy. The first clinical trial testing this a-cellular strategy has just started. However, because cell therapy is an area where different medical areas can fruitfully cross-fertilize, we have also leveraged our experience with heart failure to non cardiac indications including severe traumatic brain injury and acute respiratory distress syndromes as seen in patients with Covid-19-induced pneumonia.